Dupixent Lawsuit Explained: MDL 3180 and the CTCL Science

Last updated: October 2026

The Dupixent lawsuit is a group of federal product liability cases. They claim that Dupixent (dupilumab) caused or sped up cutaneous T-cell lymphoma (CTCL), a rare cancer that starts in the skin. In June 2026, a federal panel combined the cases into MDL No. 3180 in New Jersey. No case has been tried or settled. Whether you are just learning about the Dupixent lawsuit or deciding if it applies to you, the basics below can help you follow each step.

This guide covers what the MDL is, what the plaintiffs claim, and what the science does and does not show so far. Other posts cover symptoms and records. This one sticks to the big picture: the court case, the medical question behind it and what happens next.

What is the Dupixent lawsuit about?

Dupixent is an injectable biologic drug made by Regeneron and sold with Sanofi. It is widely prescribed for eczema (atopic dermatitis). The FDA has also approved it for asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic hives, bullous pemphigoid and allergic fungal rhinosinusitis.

People who filed suit say they developed CTCL after taking Dupixent, or that the drug made an existing, undiagnosed lymphoma grow faster. Their main legal claim is “failure to warn.” That means they argue the companies knew, or should have known, about a lymphoma risk and did not warn doctors and patients.

The companies deny these claims. Saying a claim was filed does not mean it is proven.

MDL 3180: how the federal cases were combined

On June 4, 2026, the Judicial Panel on Multidistrict Litigation (JPML) created In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180. According to the JPML transfer order, the panel moved 15 cases from 12 federal districts to the District of New Jersey. It also flagged 7 more related cases.

Key facts from the order:

• Judge: U.S. District Judge Zahid N. Quraishi, District of New Jersey.
• Defendants named: Regeneron Pharmaceuticals, Sanofi-Aventis U.S. and Genzyme Corporation.
• Scope: For now, the MDL covers CTCL and its subtypes. The panel said no plaintiff before it claimed a different kind of T-cell lymphoma. It left room to decide those cases later.
• Why combine: The panel found common questions, including whether the companies gave adequate warnings.

An MDL is not a class action. Each person keeps their own case. The judge handles shared pretrial work, like document discovery and challenges to scientific testimony, in one place. The JPML’s August 2026 docket report listed 28 pending actions in MDL 3180. That number is likely to change as more cases are filed.

What is CTCL, and why does it matter here?

CTCL is a lymphoma that shows up in the skin. The most common types are mycosis fungoides and Sézary syndrome. The National Cancer Institute describes early mycosis fungoides as a “thin, reddened, eczema-like rash.”

That overlap is central to the case. Early CTCL can look a lot like eczema. Some patients are treated for eczema for years before a biopsy shows lymphoma. That raises two questions the court will have to sort out:

• Did Dupixent cause new lymphomas, or speed up ones that were already there?
• Or were some people already living with CTCL that was mistaken for eczema, and the diagnosis just came later?

Plaintiffs argue that either way, patients and doctors deserved a warning. The companies are expected to argue that the disease came first and the drug did not cause it.

What the science says so far

The research is still developing, and it does not all point the same way. Here is what has been published and what regulators have said.

Database studies that found a link

A retrospective study published in 2024 in the Journal of the American Academy of Dermatology looked at 45,759 eczema patients. Half took dupilumab. As MDedge reported, the treated group had about four times the odds of a later CTCL diagnosis. Other researchers have reported similar signals in health-record and adverse-event data.

Limits of that research

Studies like these show an association, not proof that the drug caused the cancer. People with severe eczema may already face a higher lymphoma risk. Some diagnoses may have been missed CTCL from the start. Other studies comparing Dupixent with other systemic treatments have not found a clear increase in risk. Scientists hired by both sides will debate these questions in court. The judge will decide which opinions are reliable enough for a jury to hear.

What the FDA has said

In its October–December 2024 report of possible safety signals, the FDA listed “cutaneous T-cell lymphoma” for Dupixent. It said it “is evaluating the need for regulatory action.” A listing does not mean the FDA has found that the drug causes the problem.

As of the most recent label in the FDA’s public label database (updated August 2026), the Dupixent Warnings and Precautions section does not include lymphoma. Whether the label should have said more is the core of the failure-to-warn claims.

Where the litigation stands in October 2026

The MDL is at the very beginning. Judge Quraishi’s initial order set out early steps:

• The parties had to meet and confer by July 24, 2026.
• A joint case management report was due September 10, 2026.
• The first in-person management conference is set for October 1, 2026, in Trenton.
• A proposed initial case management order is due November 1, 2026.

Next come leadership appointments, a schedule for discovery and a plan for reports from scientific witnesses. Bellwether (test) trials, if any, are likely years away. There is no Dupixent settlement program, and no settlement amounts exist. Be cautious of anyone who quotes a payout figure.

Who may qualify to file a Dupixent lawsuit?

Every case is different, and participating law firms set their own criteria. In general, a firm may review a claim if:

• You used Dupixent before you were diagnosed.
• You were diagnosed with CTCL, mycosis fungoides, Sézary syndrome or possibly another T-cell lymphoma.
• You have records showing both your Dupixent use and your diagnosis.

Families of people who died from CTCL after using Dupixent may also be able to file. Filing deadlines vary by state and claim type, and they may start from the date of diagnosis or the date you learned of a possible link. This is why it can help to ask about your case early.

Key Legal Terms in the Dupixent Lawsuit

Court news about the Dupixent lawsuit is full of legal shorthand. This plain-language glossary explains the terms you are most likely to see in orders, news stories and law firm updates.

• MDL (multidistrict litigation): A way to send similar federal cases from many districts to one judge for shared pretrial work. Each case stays separate.
• JPML: The Judicial Panel on Multidistrict Litigation, the group of federal judges that decides whether to create an MDL and where to send it.
• Transferee judge: The judge who receives the cases. For MDL 3180, that is Judge Zahid N. Quraishi in New Jersey.
• Product liability: The area of law covering injuries said to be caused by a product, including prescription drugs.
• Failure to warn: The claim that a company did not give adequate warnings about a known or knowable risk.
• General causation: Whether a drug can cause a disease at all.
• Specific causation: Whether the drug caused the disease in one particular person.
• Discovery: The stage where each side exchanges documents, records and testimony.
• Rule 702 hearing: A hearing on whether scientific testimony is reliable enough for a jury to hear.
• Bellwether trial: An early test trial of a few selected cases, meant to show how juries may react to the evidence.
• Statute of limitations: The deadline to file a claim. It varies by state and claim type.

You do not need to memorize these terms. But knowing them makes it easier to read updates about the Dupixent lawsuit and ask clear questions.

How a Dupixent Lawsuit Typically Moves Through an MDL

Every MDL is different, and the judge sets the schedule. Still, most drug MDLs follow a similar path. Here is the general order of events a Dupixent lawsuit may follow.

1. Centralization. The JPML creates the MDL and transfers the first cases. For Dupixent, this happened in June 2026.
2. Organizing the case. The judge holds early conferences, sets rules and usually appoints lawyers to lead each side.
3. Pleadings and forms. Many MDLs use a master complaint and shorter forms for each plaintiff, plus fact sheets that ask about each person’s use and injury.
4. Discovery. The companies produce internal documents. Plaintiffs share medical and pharmacy records. Witnesses may be questioned under oath.
5. Scientific reports. Each side files reports from doctors and scientists on whether Dupixent can cause CTCL.
6. Rule 702 rulings. The judge decides which scientific opinions are reliable enough to be heard.
7. Bellwether trials or settlement talks. Some MDLs hold test trials. Others move toward settlement. Some cases end without either.
8. Remand. Cases that remain may be sent back to the courts where they started for trial.

Why the science stage matters so much

In drug cases, the scientific rulings are often a turning point. Under Federal Rule of Evidence 702, as amended in December 2023, the side offering scientific testimony must show the court that it is more likely than not reliable. If key opinions are excluded, many claims can be affected at once.

What remand means

An MDL handles pretrial work, not every trial. Under 28 U.S.C. § 1407, each transferred case is to be sent back to its original district at or before the end of pretrial proceedings, unless it has already ended.

Federal MDL vs State Court for a Dupixent Lawsuit

MDL 3180 handles federal cases. But not every Dupixent lawsuit has to be filed in federal court. Some cases may be filed in state court instead, depending on where the parties are based and other legal rules.

How the two paths differ

• Federal MDL: One federal judge manages shared pretrial work for cases from across the country.
• State court: Cases are handled under that state’s court rules. Some states group similar cases before one state judge.
• The law that applies: In both paths, state law usually governs the injury claims themselves, such as failure to warn.
• Timing: State and federal cases can move at different speeds, and rulings in one do not automatically control the other.

You do not have to choose the court yourself. A participating law firm can explain which path may fit your Dupixent lawsuit and why.

Why it can matter to you

The choice of court shapes much of what comes next. The court affects the schedule, the procedures and sometimes the deadlines. Ask any firm you speak with where it would file your case and what that means for how long it may take.

What a Plaintiff May Be Asked to Do in a Dupixent Lawsuit

Filing a case is not the end of your role. Most of the work is done by lawyers, but plaintiffs are usually asked to help at several points. Knowing this ahead of time can make a Dupixent lawsuit feel more manageable.

Share records and sign forms

You will likely sign forms that let your lawyers, and later the other side, get your medical and pharmacy records. You may also need to find old documents only you have, such as photos of your skin or pharmacy labels.

Answer written questions

Many MDLs require each plaintiff to complete a fact sheet. It may ask about your health history, your Dupixent use, your diagnosis and your treatment. Your answers are usually signed under penalty of perjury, so accuracy matters more than speed.

Give a deposition, if your case is selected

A deposition is a recorded interview under oath, usually held in a lawyer’s office or by video. Not every plaintiff is deposed. It is more common for cases picked for bellwether trials. Your lawyer will help you prepare, explain what to expect and sit with you during the questions.

Keep your lawyer updated

• Tell your firm about new diagnoses, treatments or hospital stays.
• Share any change in address, phone or email.
• Forward any letters or calls about your case from anyone else.
• Ask before posting about your health or your case online.

Be ready for a long process

Drug MDLs often take several years from the first transfer to any trials or settlement. A Dupixent lawsuit filed now may not be resolved for some time. Planning for that can reduce stress and help you focus on your health.

How to Follow Dupixent Lawsuit Updates Without Falling for Rumors

As more cases are filed, more websites will post news about the Dupixent lawsuit. Some are accurate. Others mix facts with guesses or sales pitches.

Reliable places to check

• JPML reports: The panel posts regular reports showing how many actions are pending in each MDL, including MDL 3180.
• Court orders: Orders from Judge Quraishi set schedules and rules. Federal court records can be searched through PACER, the federal courts’ public records system, which may charge small fees.
• FDA updates: Label changes and safety communications come from the FDA, not from law firm ads.
• Your own lawyer: If you have a case, your firm can explain what a new order means for you.

Tips for reading a court order

Court orders can look dense, but a few habits make them easier to follow. Start with the title and the date, which tell you what the order is about and when it was entered.

• Look for words like “ordered,” “shall” or “due,” which point to deadlines and duties.
• Check whether the order applies to all cases or only to certain plaintiffs.
• Note any upcoming conference or hearing dates.
• Remember that an order setting a schedule is not a ruling on who is right.

If an order seems to affect you, ask your lawyer before acting on it. Your firm can explain what it means for your own case.

Red flags to watch for

• Claims of “average settlement amounts” for the Dupixent lawsuit. There are no settlements as of October 2026.
• Promises that you will receive money or that a case is a sure win.
• Pressure to sign up today or lose your chance.
• Requests for payment to join a case or “reserve” a spot.
• Advice to stop taking Dupixent. Only your doctor should guide that choice.

When you see a big claim, look for the court order or official source behind it. If you cannot find one, treat the claim with caution. Staying informed through reliable sources helps you make calm, clear decisions about a possible Dupixent lawsuit.

Frequently asked questions

How Direct2Attorney can help

If you or a loved one used Dupixent and later received a lymphoma diagnosis, we can connect you with a participating law firm that may review your situation at no cost. Learn more on our Dupixent lawsuit page. You can also read which records a Dupixent CTCL claim needs.

The Dupixent lawsuit is still early, and the science is still being debated. Knowing the basics now can help you make informed choices later.

Direct2Attorney is a legal marketing and referral service, not a law firm. This article is general information, not legal advice. Submitting information does not create an attorney-client relationship.